Circassia Pharmaceuticals (CIR) Rating Reiterated by Peel Hunt
Circassia Pharmaceuticals (LON:CIR)‘s stock had its “hold” rating reissued by analysts at Peel Hunt in a research note issued to investors on Thursday, January 4th. They currently have a GBX 130 ($1.83) price objective on the biopharmaceutical company’s stock. Peel Hunt’s target price points to a potential upside of 26.21% from the stock’s current price.
Other research analysts have also issued research reports about the company. Numis Securities reiterated a “buy” rating and issued a GBX 180 ($2.53) price target on shares of Circassia Pharmaceuticals in a research report on Monday, December 4th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Circassia Pharmaceuticals in a research report on Friday, September 8th.
Circassia Pharmaceuticals (LON CIR) traded up GBX 3 ($0.04) on Thursday, reaching GBX 103 ($1.45). The company had a trading volume of 33,063 shares, compared to its average volume of 55,197. The stock has a market capitalization of $336.80 and a price-to-earnings ratio of -468.18. Circassia Pharmaceuticals has a 12 month low of GBX 76.75 ($1.08) and a 12 month high of GBX 115.61 ($1.62).
Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates.
Receive News & Ratings for Circassia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.